Overview

Effects of Ulinastatin on Coagulation in High Risk Patients Undergoing Off Pump Coronary Artery Bypass Graft Surgery

Status:
Completed
Trial end date:
2011-05-01
Target enrollment:
0
Participant gender:
All
Summary
Ulinastatin reduce the amount of bleeding and fibrinolysis in high risk patients undergoing off-pump coronary bypass surgery (OPCAB).
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Yonsei University
Treatments:
Pharmaceutical Solutions
Urinastatin
Criteria
Inclusion Criteria:

- Eighty high risk patients undergoing OPCAB (High risk patients: Euro score ≥ 6 , acute
coronary syndrome, preoperative CK-MB increased over 5 times than normal value and
high sensitivity CRP ≥2.0)

Exclusion Criteria:

- The patients who receive additional operations, the patients who don't agree to
participate in this trial, the patients who has a past hypersensitive experience on
Ulinastatin